Trial Condition(s):
Study to find out how symptoms severity changes during the standard course of treatment with the cream Relief Pro and suppositories Relief Pro (active ingredients are fluocortolone + lidocaine) in patients suffering from twisted and bulging veins in the rectal area (acute hemorrhoids)
20364
Not Available
Not Available
In this study researcher wanted to learn more about the changes of biggest twisted and bulging veins in the rectal area (hemorrhoids) and changes of symptoms during a treatment period with the cream Relief Pro and suppositories Relief Pro. The study collected information on the treatment satisfaction of patients and their physicians with the prescribed treatment by using questionnaires. There were 3 visits at the physician's clinic for this study: one initial visit and 2 follow-up visits over a period of 2 weeks.
- Male & female patients 18 to 65 years old; - Patients with acute hemorrhoids 1 and 2 stage (with thrombosis (external, internal, mixed), including cases with bleeding); - Prescription of fluocortolone + lidocaine as a part of routine clinical practice.
- Patients participating in an investigational program with interventions outside of routine clinical practice; - Hemorrhoid with stage ˃ II; - Contraindications for use of Relief PRO in the approved product label; - Anemia and/or severe/profuse hemorrhoid bleeding; - Surgery in perianal region in anamnesis; - Concomitant treatment with antibiotics/antiseptics, antithrombotics, antineoplastic and/or immunosuppressant; - Inflammatory bowel disease; - Hepatic diseases in severe and acute stages; - Colorectal cancer; - Purulent-inflammatory diseases of the perianal region and anal canal; - Chronic pulmonary diseases in severe and acute stages.
Locations | |
---|---|
Locations State Scientific Center of Coloproctology Moscow, Russia, 123423 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Prospective multicenter non-interventional study of fluocortolone + lidocaine formulation in patients with acute hemorrhoids to evaluate changes in symptoms severity during the course of treatment
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1